A promising new development in breast cancer screening could soon offer a more accessible and less invasive method for early detection. Researchers at the University of Florida Health, in collaboration with scientists from Taiwan’s National Yang Ming Chiao Tung University, have developed a saliva-based test that may transform how breast cancer is detected and monitored. In a small study involving 29 saliva samples, this handheld biosensor device identified breast cancer with 100% accuracy and correctly ruled out the disease in 86% of cases. While further research is needed, the implications for breast cancer screening and healthcare accessibility are significant.

This innovative approach to breast cancer detection uses a portable biosensor to analyze specific biomarkers found in saliva. The device, which fits comfortably in the palm of a hand, is designed to be user-friendly and accessible, especially for those in rural or underserved communities. I found this detail striking because it suggests a future where early detection could happen from the comfort of one’s home, potentially reducing both logistical and emotional barriers to screening.

Dr. Coy Heldermon, a breast oncologist and co-author of the study, emphasized the potential of this technology to improve access to screening and significantly reduce healthcare costs. “If all holds true, it would be a game-changer,” Heldermon said in a University of Florida news release. Access to timely screening remains a major hurdle in breast cancer care, particularly in areas where medical facilities are scarce or where patients face challenges in scheduling traditional tests like mammograms.

The American Cancer Society currently recommends that women at average risk begin mammogram screenings at age 40. For those with additional risk factors, such as a family history of the disease, MRIs may also be advised. However, these procedures can be time-consuming, uncomfortable, and require in-person appointments. Study senior author Dr. Josephine Esquivel-Upshaw, who lost her mother to breast cancer and is herself at high risk, described the current process as a “hassle” and “discouraging.” She noted that she undergoes both a mammogram and a breast MRI every six months. The idea of replacing these frequent visits with a simple saliva test at home is understandably appealing.

The biosensor works by detecting breast cancer biomarkers in saliva. Patients provide a sample in a sterile cup, and a test strip is immersed in the saliva for about three seconds. This strip is then inserted into the device’s circuit board, which contains multi-channel test strips capable of identifying several biomarkers. Results are available in real time through a connected mobile app, making the process swift and user-friendly.

The technology was developed through a cross-disciplinary collaboration between medical researchers and electrical engineers. According to the team, the circuit board and sensor platform were designed to be compact and portable without compromising sensitivity. “We were able to shrink the sensor platform so it fits in the palm of your hand, which was our whole drive: to make this accessible and portable for patients to be able to use,” Esquivel-Upshaw explained.

In the initial study, the biosensor accurately identified all cases of breast cancer among the 29 samples tested. It also correctly identified individuals without the disease 86% of the time. While the sample size is small, these early results are encouraging and suggest that the device could serve as a preliminary screening tool. Patients who receive a positive result could then be referred for follow-up testing, such as a mammogram or MRI.

Heldermon elaborated on this potential use case: “You send in some spit or better yet have the sensor sent to you, it does the measurement and if it's positive, you get sent for additional testing. That is so much more practical and would have so much better uptake among patients.”

Currently, the research team is focused on refining the technology by testing additional saliva biomarkers to determine which combinations offer the most accurate predictions. They are also exploring the potential for the device to detect other diseases beyond breast cancer. Given the non-invasive nature of saliva sampling and the portability of the device, the possibilities for broader medical applications are considerable.

The study, published in the journal Biosensors, outlines the technical aspects of the biosensor and its early performance metrics. While more extensive trials will be necessary to validate these findings, the initial data offers hope for a future where breast cancer screening is more accessible, less invasive, and potentially more widely adopted.

This development arrives at a time when healthcare systems worldwide are seeking ways to improve early detection and reduce the burden on both patients and providers. A saliva-based test that is accurate, affordable, and easy to use could represent a significant step forward in public health, particularly for communities that currently face barriers to traditional screening methods.

As research continues and the technology is refined, the hope is that this biosensor could become a standard tool in the early detection of breast cancer, ultimately improving outcomes and saving lives.

Read more at medicalxpress.com